title: The antitumor activity of tumor-homing peptide-modified thermosensitive liposomes containing doxorubicin on MCF-7/ADR: in vitro and in vivo.
abstract: Clotted plasma proteins are present on the walls of tumor vessels and in tumor stroma. Tumor-homing peptide Cys-Arg-Glu-Lys-Ala (CREKA) could recognize the clotted plasma proteins in tumor vessels. Thermosensitive liposomes could immediately release the encapsulated drug in the vasculature of the heated tumor. In this study, we designed a novel form of targeted thermosensitive liposomes, CREKA-modified lysolipid-containing thermosensitive liposomes (LTSLs), containing doxorubicin (DOX) (DOX-LTSL-CREKA), to investigate the hypothesis that DOX-LTSL-CREKA might target the clotted plasma proteins in tumor vessels as well as tumor stroma and then exhibit burst release of the encapsulated DOX at the heated tumor site. We also hypothesized that the high local drug concentration produced by these thermosensitive liposomes after local hyperthermia treatment will be useful for treatment of multidrug resistance. The multidrug-resistant human breast adenocarcinoma (MCF-7/ADR) cell line was chosen as a tumor cell model, and the targeting and immediate release characteristics of DOX-LTSL-CREKA were investigated in vitro and in vivo. Furthermore, the antitumor activity of DOX-LTSL-CREKA was evaluated in MCF-7/ADR tumor-bearing nude mice in vivo. The targeting effect of the CREKA-modified thermosensitive liposomes on the clotted plasma proteins was confirmed in our in vivo imaging and immunohistochemistry experiments. The burst release of this delivery system was observed in our in vitro temperature-triggered DOX release and flow cytometry analysis and also by confocal microscopy experiments. The antitumor activity of the DOX-LTSL-CREKA was confirmed in tumor-bearing nude mice in vivo. Our findings suggest that the combination of targeting the clotted plasma proteins in the tumor vessel wall as well as tumor stroma by using CREKA peptide and temperature-triggered drug release from liposomes by using thermosensitive liposomes offers an attractive strategy for chemotherapeutic drug delivery to tumors.
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Chao
authors.initials: C
authors.lastname: Wang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Xin
authors.initials: X
authors.lastname: Wang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Ting
authors.initials: T
authors.lastname: Zhong
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Wei-Qiang
authors.initials: WQ
authors.lastname: Zhang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Ren
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Dan
authors.initials: D
authors.lastname: Huang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Shuang
authors.initials: S
authors.lastname: Zhang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Yang
authors.initials: Y
authors.lastname: Guo
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Xin
authors.initials: X
authors.lastname: Yao
authors.affiliation: Department of Clinical Pharmacy, China Pharmaceutical University, Nanjing, People's Republic of China.
authors.forename: Yi-Qun
authors.initials: YQ
authors.lastname: Tang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Xuan
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China ; State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, People's Republic of China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Zhang
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000494:pharmacology; D004317:Doxorubicin / Q000008:administration & dosage / Q000494:pharmacology*; D016503:Drug Delivery Systems / Q000379:methods*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006358:Hot Temperature; D006801:Humans; D006979:Hyperthermia, Induced / Q000379:methods*; D008081:Liposomes / Q000737:chemistry* / Q000494:pharmacology*; D061986:MCF-7 Cells / Q000187:drug effects; D051379:Mice; D008819:Mice, Nude; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D009842:Oligopeptides / Q000737:chemistry* / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D009842:Oligopeptides; C542438:cysteinyl-arginyl-glutamyl-lysyl-alanyl; D004317:Doxorubicin
keywords: clotted plasma protein; lysolipid-containing thermosensitive liposomes; targeting; tumor-homing peptide Cys-Arg-Glu-Lys-Ala (CREKA)
references.citation: Nat Rev Drug Discov. 2006 Mar;5(3):219-34
references.pmid: 16518375
references.citation: Drug Discov Today. 2012 Feb;17(3-4):160-6
references.pmid: 21983329
references.citation: Small. 2008 Nov;4(11):2043-50
references.pmid: 18949788
references.citation: J Control Release. 2014 Jan 28;174:202-8
references.pmid: 24269966
references.citation: Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):932-6
references.pmid: 17215365
references.citation: Neoplasia. 2002 Nov-Dec;4(6):465-73
references.pmid: 12407439
references.citation: ACS Nano. 2011 Jun 28;5(6):4919-26
references.pmid: 21591812
references.citation: Biochem J. 2002 Nov 1;367(Pt 3):729-40
references.pmid: 12139490
references.citation: Cancer Res. 2003 Nov 1;63(21):7400-9
references.pmid: 14612539
references.citation: J Control Release. 2011 Sep 25;154(3):290-7
references.pmid: 21640149
references.citation: J Control Release. 2012 Jul 10;161(1):142-9
references.pmid: 22504351
references.citation: Int J Nanomedicine. 2014;9:4671-83
references.pmid: 25336947
references.citation: Med Chem. 2011 Sep;7(5):504-17
references.pmid: 21801147
references.citation: Int J Nanomedicine. 2013;8:2473-85
references.pmid: 23885174
references.citation: J Pharm Sci. 2010 May;99(5):2295-308
references.pmid: 19902527
references.citation: J Control Release. 2011 Jul 30;153(2):187-94
references.pmid: 21501640
references.citation: Mol Cancer Ther. 2004 Oct;3(10):1311-7
references.pmid: 15486198
references.citation: J Control Release. 2010 Apr 19;143(2):265-73
references.pmid: 20067811
references.citation: Biomaterials. 2014 Mar;35(9):3091-101
references.pmid: 24406217
references.citation: J Control Release. 2008 Jan 22;125(2):112-20
references.pmid: 18022271
references.citation: Cancer Res. 2000 Dec 15;60(24):6950-7
references.pmid: 11156395
references.citation: J Control Release. 2011 Nov 7;155(3):358-66
references.pmid: 21745505
references.citation: Biomaterials. 2010 Sep;31(27):7096-105
references.pmid: 20580431
references.citation: Asian Pac J Cancer Prev. 2008 Jan-Mar;9(1):1-6
references.pmid: 18439063
references.citation: Adv Drug Deliv Rev. 2001 Dec 31;53(3):265-72
references.pmid: 11744171
references.citation: Open Nanomed J. 2011 Jan 1;3:38-64
references.pmid: 23807899
references.citation: Cancer Res. 2012 Nov 1;72(21):5566-75
references.pmid: 22952218
references.citation: Int J Nanomedicine. 2012;7:2261-9
references.pmid: 22619560
references.citation: Cancer Res. 2000 Mar 1;60(5):1197-201
references.pmid: 10728674
references.citation: J Control Release. 2011 Nov 7;155(3):442-8
references.pmid: 21689699
references.citation: Bioconjug Chem. 2008 Dec;19(12):2300-3
references.pmid: 19053180
references.citation: J Nanosci Nanotechnol. 2012 May;12(5):4044-50
references.pmid: 22852345
references.citation: Science. 1978 Dec 22;202(4374):1290-3
references.pmid: 364652
references.citation: Blood. 2010 Oct 14;116(15):2847-56
references.pmid: 20587786
references.citation: J Control Release. 2011 Jun 10;152(2):303-9
references.pmid: 21338635
references.citation: J Med Chem. 2010 May 13;53(9):3782-92
references.pmid: 20405849
references.citation: Nanomedicine. 2009 Mar;5(1):73-82
references.pmid: 18829396
references.citation: J Control Release. 2014 Jan 10;173:43-50
references.pmid: 24511611
references.citation: Int J Nanomedicine. 2014;9:3091-105
references.pmid: 25028548
references.citation: Nat Biotechnol. 1997 Nov;15(12):1271-5
references.pmid: 9359110
references.citation: Front Pharmacol. 2014 Jul 10;5:159
references.pmid: 25071577
references.citation: Adv Drug Deliv Rev. 2013 Nov;65(13-14):1784-802
references.pmid: 23880506
references.citation: Cancer Res. 2002 Apr 1;62(7):2034-42
references.pmid: 11929822
references.citation: Nat Protoc. 2006;1(3):1112-6
references.pmid: 17406391
references.citation: Expert Opin Pharmacother. 2009 Feb;10(2):333-43
references.pmid: 19236203
references.citation: J Control Release. 2013 Dec 28;172(3):885-93
references.pmid: 24075924
references.citation: Science. 1979 Apr 13;204(4389):188-91
references.pmid: 432641
references.citation: Biochim Biophys Acta. 2005 Oct 15;1716(2):77-96
references.pmid: 16216216
references.citation: Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8663-8
references.pmid: 10411932
references.citation: Cancer Res. 1995 Sep 1;55(17):3752-6
references.pmid: 7641188
references.citation: J Biochem Mol Biol Biophys. 2002 Oct;6(5):309-14
references.pmid: 12385965
references.citation: Photochem Photobiol. 2009 Jul-Aug;85(4):848-60
references.pmid: 19222790
references.citation: J Control Release. 2010 Apr 19;143(2):274-9
references.pmid: 20074595
references.citation: Int J Nanomedicine. 2014;9:4387-98
references.pmid: 25258529
references.citation: Acta Biomater. 2014 Jun;10(6):2622-9
references.pmid: 24486913
references.citation: Science. 1985 Mar 1;227(4690):1059-61
references.pmid: 3975602